全文获取类型
收费全文 | 8129篇 |
免费 | 656篇 |
国内免费 | 543篇 |
专业分类
耳鼻咽喉 | 86篇 |
儿科学 | 46篇 |
妇产科学 | 19篇 |
基础医学 | 552篇 |
口腔科学 | 85篇 |
临床医学 | 1036篇 |
内科学 | 971篇 |
皮肤病学 | 26篇 |
神经病学 | 270篇 |
特种医学 | 404篇 |
外国民族医学 | 14篇 |
外科学 | 1107篇 |
综合类 | 1584篇 |
现状与发展 | 1篇 |
预防医学 | 1031篇 |
眼科学 | 165篇 |
药学 | 927篇 |
中国医学 | 197篇 |
肿瘤学 | 807篇 |
出版年
2024年 | 4篇 |
2023年 | 58篇 |
2022年 | 105篇 |
2021年 | 139篇 |
2020年 | 145篇 |
2019年 | 105篇 |
2018年 | 88篇 |
2017年 | 83篇 |
2016年 | 122篇 |
2015年 | 175篇 |
2014年 | 691篇 |
2013年 | 705篇 |
2012年 | 1122篇 |
2011年 | 1056篇 |
2010年 | 680篇 |
2009年 | 562篇 |
2008年 | 563篇 |
2007年 | 682篇 |
2006年 | 430篇 |
2005年 | 282篇 |
2004年 | 215篇 |
2003年 | 246篇 |
2002年 | 197篇 |
2001年 | 155篇 |
2000年 | 152篇 |
1999年 | 157篇 |
1998年 | 85篇 |
1997年 | 119篇 |
1996年 | 57篇 |
1995年 | 45篇 |
1994年 | 34篇 |
1993年 | 43篇 |
1992年 | 12篇 |
1991年 | 9篇 |
1990年 | 4篇 |
1989年 | 1篇 |
排序方式: 共有9328条查询结果,搜索用时 15 毫秒
1.
日间手术在国外已有上百年的发展历史,现已成为欧美国家重要手术模式。我国于20世纪初开始开展日间手术,但目前尚未普及,发展不平衡问题比较突出,存在认识不清、开展不规范、与医保支付对接不畅等问题。日间手术是一种使国家、医院和病人三方均受益的新型手术模式。近年来,国家相关管理部门积极引导,开展日间手术的医院明显增多,可以预见,我国日间手术即将进入快速发展的新阶段。因此,有条件的医院可以从简单、易操作的病种开始,落实临床路径,积累经验,再逐步稳妥展开。在保证质量的前提下,不断拓展日间手术范围,提高三、四级手术比例。同时,积极与医保支付政策对接,采取灵活的方式,获得医保的支持,更好地促进我国日间手术的快速发展。 相似文献
2.
目的探讨多原发结直肠癌的临床特征和预后。方法回顾性分析南京医科大学第一附属医院2013年1月至2018年12月收治的42例多原发结直肠癌患者的临床资料,对其临床病理特征、诊治及预后进行总结。结果符合多原发结直肠癌诊断的患者42例,占同期收治的所有结直肠癌患者的1.20%(42/3499),病理类型以腺癌为主。其中,同时性多原发癌32例,年龄38~86岁,中位年龄66岁,共发现73处结直肠癌灶,多位于近端结肠、乙状结肠及直肠;共检出淋巴结527枚,阳性10枚(1.9%),淋巴结阳性患者占同时性多原发癌的37.5%(12/32);27例为双原发癌,3例为三原发癌,2例为五原发癌;1、3年总生存率分别为83.75%和74.38%。异时性多原发癌10例,年龄33~86岁,第一癌多位于直肠和乙状结肠区域,第二癌多位于升结肠区域;共检出淋巴结276枚,阳性率12.3%(34枚),1、3年总生存率分别为100.00%和66.67%。结论多原发结直肠癌在临床上不少见,其分布有一定规律。临床中应引起重视,提高早期诊断率。应早期手术治疗以提高患者的生存率。 相似文献
3.
目的观察阿帕替尼联合曲妥珠单抗杀伤胃癌NCI-N87细胞的协同增敏作用并探讨可能作用机制。方法CCK-8法检测空白对照组、曲妥珠单抗组(0.1、1、10μg/ml)、阿帕替尼组(1μmol/L)及曲妥珠单抗(0.1、1、10μg/ml)+阿帕替尼(1μmol/L)组对NCI-N87细胞的增殖抑制作用,流式细胞术检测NCI-N87细胞凋亡,Western blotting检测HER-2、VEGFR2、Bax、Bcl-2蛋白表达。结果CCK-8检测提示曲妥珠单抗、阿帕替尼能够抑制NCI-N87细胞增殖,在一定浓度范围内作用呈浓度依赖性和时间依赖性(P<0.01);q值计算提示曲妥珠单抗与阿帕替尼具有协同抑制NCI-N87细胞增殖的作用。流式细胞术检测显示联合组NCI-N87胃癌细胞凋亡较单药组明显升高(P<0.05),其中空白对照组、阿帕替尼组(1μmol/L)、曲妥珠单抗(0.1μg/ml)组及曲妥珠单抗(0.1μg/ml)+阿帕替尼(1μmol/L)组的凋亡率分别为(3.0±1.28)%、(5.8±1.63)%、(8.0±3.92)%和(21.6±6.85)%。曲妥珠单抗+阿帕替尼组与空白对照组、曲妥珠单抗及阿帕替尼单药组比较,HER-2蛋白表达显著下调(P<0.05);曲妥珠单抗+阿帕替尼组与空白对照组比较,Bcl-2蛋白表达、Bcl-2/Bax比值明显降低(P<0.01)。结论阿帕替尼联合曲妥珠单抗可能通过下调HER-2蛋白及调控凋亡相关蛋白Bcl-2、Bax的表达,协同抑制NCI-N87细胞增殖和促进细胞凋亡。 相似文献
5.
Huang Kangmo Zha Mingming Gao Jie Du Juan Liu Rui Liu Xinfeng 《Journal of thrombosis and thrombolysis》2021,51(2):536-544
Journal of Thrombosis and Thrombolysis - The impact of atrial fibrillation (AF) on outcomes of mechanical thrombectomy (MT) for acute ischemic stroke (AIS) is controversial, and with a paucity of... 相似文献
6.
BackgroundPatients awaiting kidney transplantation are regularly screened for HLA-antibodies, but there is scarce data about the optimal interval.MethodsResults from Complement-dependent cytotoxicity testing (CDC) for waitlisted patients were reviewed for increases in panel reactive antibodies (PRA) by at least 10%-points. Clinical records were screened for historic immunizing events and possible trigger factors preceding the PRA-increase. Additionally, non-pretransplanted men tested negative for HLA antibodies by solid-phase assays (SPA) out of their first two samples on the waiting list (“non-immunized men”) were evaluated for detection of HLA antibodies by SPA during their further stay on the waiting list.Results15,360 samples from 1928 patients tested by CDC were analyzed for changes in PRA. PRA-increases occurred most frequently in patients waitlisted recently for retransplantation (annual incidence 6%). Removal of previous transplants, severe infections and/or reduced immunosuppression triggered 65% of PRA-increases during the first year after waitlisting. Transfusions accounted for 55% of PRA-increases in later years. Leucocyte-reduced red blood cell units not only boosted historic antibodies, but even induced primary immunization. In the second part of the study, 6780 samples tested by SPA from 703 non-immunized men were evaluated for development of HLA-antibodies. Only 9 men (1.3%) turned HLA antibody-positive (annual incidence 0.4%).ConclusionA uniform screening interval does not fit all: Frequencies should be highest in patients newly waitlisted for re-transplant and lowest in non-immunized men. Transfused patients should be monitored closely for development of HLA-antibodies even if leukoreduced products are used. 相似文献
7.
MicroRNA-155(miR-155) and protein prenylation have been reported to participate in acute graft-versus-host disease (aGVHD) through modulating T lymphocyte differentiation, however the mechanism remains elusive. In this study, we found that the expression of miR-155 and protein prenyltransferases in peripheral blood T lymphocytes of aGVHD mice was significantly increased. Suppression of miR-155 by antagomir-155 could remarkably reduce prenyltransferases mRNA and protein expression in T lymphocytes of aGVHD mice. Conversely, prenyltransferase inhibitors significantly reduced the level of miR-155. Inhibition of this feedback loop of miR-155 and protein prenylation in aGVHD mice led to improved survival and lower aGVHD histopathology scores and significantly induced T cell deficient differentiation towards T helper 17 (Th17) cells and titled differentiation towards CD4+CD25hi regulatory T (Treg) cells. Furthermore, the immunoregulatory effects and protection from aGVHD of prenyltransferase inhibitors could be reversed by the addition of miR-155. The dual treatment of prenylation inhibitors and antagomir-155 showed synergistic effects on T polarization and protection from aGVHD. Consistent with the in vivo changes, inhibition of this feedback loop of miR-155 and protein prenylation affected Th17 and Treg cell polarization in vitro. Our data suggest that miR-155 and protein prenylation may constitute a feedback loop that amplifies immune and inflammatory responses in subjects with aGVHD, and they may serve as potential targets for aGVHD prophylaxis and treatment. 相似文献
8.
9.
【摘要】 研究表明,甲氨蝶呤皮下注射较口服途径可以获得更快、更好的吸收和更高的血药浓度以及较低的生物利用度变异度。在类风湿关节炎患者和银屑病患者,甲氨蝶呤皮下注射的疗效显著优于口服途径,并且胃肠道不良反应发生率更低。对于甲氨蝶呤口服疗效欠佳或者不耐受的患者,改为皮下注射后仍然可以获得较好的治疗反应。甲氨蝶呤皮下注射可以作为生物制剂使用前的治疗选择,可节省大量费用。总之,甲氨蝶呤皮下注射具有较好的临床应用前景。 相似文献
10.
??This paper reviewed benefit and risk of myopathy and rhabdomyolysis in statins with guide and following the medical evidence.The chemical structure of statins is closely related to the effect and heterogeneity of the drugs. The use of statins including atorvastatin,rosuvastatin can give patients more clinical benefit when strengthen to low blood lipid. Although rosuvastatin in statins is strongest, but presence of sulphonamide group resulted in the increase of its toxicity, It show that rosuvastatin risk for rhabdomyolysis was significantly higher than that of atorvastatin statins by foreign evidence. Therefore, the patients following with multiple risk factors need to use caution with the choice of rosuvastatin. Recently rosuvastatin causing myopathy and rhabdomyolysis cases in the world has increased, It should arouse the attention of clinical. Clinical pharmacists should focus more on pathophysiological state, interaction, drug genome science to proceed, so we can summarize and analyze the occurrence regularity, and investigate its mechanism in order to protect the safety of patients with medication. It can help clinical pharmacists to take responsibility for the uprising. 相似文献